WASHINGTON, June 2 -- National Institutes of Health has issued a notice called: Prospective Grant of an Exclusive Patent License: Exceptionally Selective D2 Dopamine Receptor Antagonists as Therapeutics.
The notice was published in the Federal Register on June 2 by Susan E. Ano, Chief, Technology Transfer Branch, National Institute of Neurological Disorders and Stroke.
Summary: The National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplem...